Peginterferon beta-1a (Plegridy) for multiple sclerosis.
Pegylated interferon beta-1a (Plegridy) injected subcutaneously every 2 weeks appears to be similar in its efficacy and adverse effects to older interferon formulations that must be injected more frequently.
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D007279:Injections, Subcutaneous; D016899:Interferon-beta / Q000008:administration & dosage*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage*
D011092:Polyethylene Glycols; D016899:Interferon-beta; C428112:peginterferon beta-1a